Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Bridgewater

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Biorxiv : the Preprint Server for Biology|February 26, 2024
Epigenome and early selection determine the tumour-immune evolutionary trajectory of colorectal cancerEszter Lakatos, Vinaya Gunasri, Luis Zapata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2018
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal CancerAndrew G Hill, Michael P Findlay, Matthew E Burge, et al.
Future Oncology (London, England)|July 29, 2025
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabineEleni Vrana, Hayley Timmins, Ashley Osborne, et al.
Lancet (London, England)|June 7, 2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialTimothy S Maughan, Richard A Adams, Christopher G Smith, et al.
The Lancet. Oncology|June 5, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J Harding, Jia Fan, Do-Youn Oh, et al.
Journal of Hepatology|June 5, 2025
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancerFlorian Castet, Carles Fabregat-Franco, John Bridgewater, et al.
Targeted Oncology|December 16, 2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancerJean-Luc Van Laethem, Hanno Riess, Jacek Jassem, et al.
JAMA Oncology|November 20, 2025
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01Shubham Pant, Jia Fan, Do-Youn Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP StudyJohn Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
The Lancet. Gastroenterology & Hepatology|September 4, 2019
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam-Hogan, Fay Cafferty, Richard Hubner, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Biorxiv : the Preprint Server for Biology|February 26, 2024
Epigenome and early selection determine the tumour-immune evolutionary trajectory of colorectal cancerEszter Lakatos, Vinaya Gunasri, Luis Zapata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2018
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal CancerAndrew G Hill, Michael P Findlay, Matthew E Burge, et al.
Future Oncology (London, England)|July 29, 2025
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabineEleni Vrana, Hayley Timmins, Ashley Osborne, et al.
Lancet (London, England)|June 7, 2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialTimothy S Maughan, Richard A Adams, Christopher G Smith, et al.
The Lancet. Oncology|June 5, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J Harding, Jia Fan, Do-Youn Oh, et al.
Journal of Hepatology|June 5, 2025
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancerFlorian Castet, Carles Fabregat-Franco, John Bridgewater, et al.
Targeted Oncology|December 16, 2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancerJean-Luc Van Laethem, Hanno Riess, Jacek Jassem, et al.
JAMA Oncology|November 20, 2025
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01Shubham Pant, Jia Fan, Do-Youn Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP StudyJohn Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
The Lancet. Gastroenterology & Hepatology|September 4, 2019
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam-Hogan, Fay Cafferty, Richard Hubner, et al.
Pageof 13